1. Very important comment
    TonyDewitt TonyDewitt United States says:
    August 17, 2012 at 1:48 PM

    The hidden surprise in Tofacitinib is that since it is a JAK inhibitor, it will be effective against two disorders caused by HTLV: HAM and ATL. Once it is approved, 25 million HTLV sufferers will ask their doctors for this drug in order to fight HAM (which leads to being in a wheelchair) and ATL (which leads to being dead from a rapid leukemia). Other JAK inhibitors besides Tofacitinib include AG490.

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback